Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Join SI Premium – FREE
Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.72), $0.09 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $1.27 million versus the consensus estimate of $11.16 million.
For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- HCI Group (HCI) Tops Q3 EPS by 245c
- Suncor Energy (SU) Tops Q3 EPS by 172c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
